Announcements Trials
Browse Landscape

Phase

Phase 2 9Phase 1/2 3Phase 3 2Phase 1 2Phase 2/3 1

Status

Completed 19Terminated 8Unknown 4Withdrawn 3Active not recruiting 3Recruiting 2

Sponsor Class

OTHER 2NIH 1

Study Type

Interventional 3

Sponsor

Cancer Type

Other hematologic neoplasm 3Myeloid 1Lymphoid 1Classical hematology 1

Conditions

Leukemia, Myeloid, Acute 2Shwachman-Diamond Syndrome 1Primary Immunodeficiency Diseases 1Precursor Cell Lymphoblastic Leukemia-Lymphoma 1Neutropenia, Severe Congenital, Autosomal Recessive 3 1Myelodysplastic Syndromes 1Macrophage Activation Syndrome 1Lymphoma 1Lymphohistiocytosis, Hemophagocytic 1Leukemia, Myelomonocytic, Juvenile 1Leukemia, Myelogenous, Chronic, BCR-ABL Positive 1Histiocytosis, Langerhans-Cell 1Histiocytosis 1Hemoglobinopathies 1Hematologic Neoplasms 1Graft vs Host Disease 1Bone Marrow Failure Disorders 1Anemia, Sickle Cell 1Anemia, Diamond-Blackfan 1Anemia, Aplastic 1Acquired Immunodeficiency Syndrome 1

Interventions

pembrolizumab 69Nivolumab 39Cyclophosphamide 35Carboplatin 27Dexamethasone 23Specimen Handling 22Paclitaxel 22Lenalidomide 22durvalumab 20Radiotherapy 19Gemcitabine 19venetoclax 18Magnetic Resonance Spectroscopy 18Doxorubicin 17Rituximab 16Ipilimumab 16fludarabine 15Bevacizumab 15Biopsy 14atezolizumab 13Etoposide 13Vincristine 12Cisplatin 12Azacitidine 12belantamab mafodotin 11Pemetrexed 11Docetaxel 11Calcium Dobesilate 11olaparib 10Oxaliplatin 10

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

3 trials
RecentStart dateEnrollment
Phase 1/2 × Active not recruiting × Busulfan × Clear all
NCT03983850 2025-12-26

Optimizing PTCy Dose and Timing

National Institutes of Health Clinical Center (CC)

Phase 1/2 Active not recruiting
105 enrolled
Other hematologic neoplasm

Graft vs Host Disease, Hematologic Neoplasms

NCT03247088 2025-12-15

Sorafenib, Busulfan and Fludarabine in Treating Patients With Recurrent or Refractory Acute Myeloid Leukemia Undergoing Donor Stem Cell Transplant

M.D. Anderson Cancer Center

Phase 1/2 Active not recruiting
74 enrolled
Other hematologic neoplasm

Leukemia, Myeloid, Acute

NCT02061800 2024-06-04

CD34+ (Malignant) Stem Cell Selection for Patients Receiving Allogenic Stem Cell Transplant

Columbia University

Phase 1/2 Active not recruiting
14 enrolled
Classical hematologyLymphoidMyeloidOther hematologic neoplasm

Neutropenia, Severe Congenital, Autosomal Recessive 3, Bone Marrow Failure Disorders, Shwachman-Diamond Syndrome, Primary Immunodeficiency Diseases, Acquired Immunodeficiency Syndrome, Anemia, Aplastic, Anemia, Sickle Cell, Hemoglobinopathies, Histiocytosis, Langerhans-Cell, Lymphoma, Myelodysplastic Syndromes, Leukemia, Myelogenous, Chronic, BCR-ABL Positive, Leukemia, Myeloid, Acute, Histiocytosis, Anemia, Diamond-Blackfan, Lymphohistiocytosis, Hemophagocytic, Precursor Cell Lymphoblastic Leukemia-Lymphoma, Leukemia, Myelomonocytic, Juvenile, Macrophage Activation Syndrome

Data powered by HemOnc (CC BY 4.0) Colophon âš¡